Published: 2022 November 02

Tuberculosis Drug Market Size, Competitive Landscape and Market Forecast - 2029

SKU : PH881
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Tuberculosis Drug Market is segmented By Therapy Type (First Line Drugs Therapy, Second Line Drugs Therapy, Combination Drugs Therapy), By Type (Latent TB Type, Active Type), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Tuberculosis Drug Market was valued at US$ 1,755.29 million in 2021 and is estimated to reach US$ 2,407.35 million by 2029, growing at a CAGR of 9.68% during the forecast period (2022-2029).      

Tuberculosis Drug Market - Strategic Insights



Market CAGR


Segments Covered

By TB Type, By Therapy Type, By Distribution Channeland By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here   

Tuberculosis (TB), known as poor man’s disease, is caused by mycobacterium tuberculosis germs spread from person to person through the air. Tuberculosis drugs are also used post surgeries of the stent, bypass surgery, and others. TB usually affects the lungs and other parts of the body, such as the brain, the kidneys, or the spine. Across the globe, almost two billion people are infected with M. tuberculosis.

Market Dynamics

The increasing demand for these drugs due to the rising incidence of tuberculosis, MDR-TB and TB-HIV co-infection, the increasing research and development expenditure and growth in studies and novel product launches are expected to drive market growth.

The increasing novel product launches and demand for tuberculosis drugs will drive market growth.     

The global market for tuberculosis drugs is primarily driven by the healthcare industry's demand for tuberculosis due to increasing tuberculosis cases. The emergence of MDR-TB and XDR-TB strains and an increase in an outbreak of TB-HIV co-infection are also driving the market’s growth. Studies are being conducted on novel tuberculosis drugs to examine their safety, efficacy and other capabilities. For instance, in Mar 2022, Qurient Co. announced its phase 2 clinical trial results, an open-label trial for proving Telacebec, a novel anti-tuberculosis drug concept in humans that was published in the New England Journal of Medicine. This trial involved 61 newly diagnosed patients with pulmonary tuberculosis that received combination therapy and reported that increasing telacebec doses was related to a huge reduction in time to the positivity of the collected samples of sputum.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these tuberculosis drugs. For instance, in Jan 2022, TB Alliance, a non-profitable organization, announced the funding received for starting research on novel treatments for tuberculosis by United States Agency for International Development. Around US$ 30 Million in funding will be provided for 5 years, under which TB Alliance will search for novel treatments for tuberculosis and optimize the available treatments for adults and children. This will provide strength to health systems in TB-burden countries.

The high costs associated with tuberculosis drugs will hamper the market’s growth.  

However, high rates for a quality-assured regimen make anti-TB drugs almost unaffordable in developing nations. Lack of easy access to diagnostics, low priority in national treatment programs, and high costs of treatment are some of the chief features of this market.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The tuberculosis drugs market has experienced huge losses due to shifting all the attention to COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the industry, preparing and implementing backup plans as soon as possible for business operations is crucial. Various initiatives, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Oct 2022, Cadila Pharmaceutical, for its ‘end of the global epidemic TB campaign initiative, was declared one of the world's best record holders by

Segment Analysis

The active TB type segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)          

The active tuberculosis type segment is the highest market holder in the global tuberculosis drugs market. Active TB  is also known as TB disease, as the TB bacteria gets activated when the immune system cannot stop the growth of bacteria. As these bacteria become active, i.e., multiplies in the body, this becomes a disease. Various individuals get infected with TB and, if not treated, can develop TB disease later. People get sick if they have TB disease; they may spread the bacteria to others and need proper treatment for TB disease.

Active TB dominates the market due to increased tuberculosis cases globally. According to the World Health Organization, in 2020, approximately 1.3 million people died from tuberculosis. The rising number of people suffering from tuberculosis and growing technological advancements or research/ clinical trial studies drive the market’s growth. For Instance, in Aug 2022, the collaboration PAN-TB Project to Accelerate New treatments for Tuberculosis announced about joint development agreement execution that will support the progression of phase 2 clinical development of 2 investigational tuberculosis combination treatment regimens. This collaboration will examine the effectiveness of the combination of new chemical entities and registered products in treating active pulmonary TB and its various forms.

Geographical Analysis

Asia-Pacific region holds the largest market share of the global tuberculosis drugs market.

Asia-Pacific dominates the global antiplatelet drug market, primarily attributed to the rising prevalence of tuberculosis infection due to unhealthy lifestyles such as smoking and changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to the Asia Pacific region’s rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the World Health Organization, 10 million people got tuberculosis, the largest amount, with around 43% of new TB cases occurring in the Southeast Asian region in 2020. Around 8 countries accounted for about two-thirds of novel TB cases, including India, China, Bangladesh, Indonesia, Pakistan, Philippines and more.

Moreover, the growing number of product launches is responsible for the market’s growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market’s growth. Many key developments and technological advancements are taking place based in this region. For instance, In Sep 2022, TB Alliance, a non-profitable organization that develops and provides drugs for fighting tuberculosis, is in talks with the government of India for the BPal regimen’s recommended usage in India’s TB control program.

Competitive Landscape 

The tuberculosis drugs market is highly competitive with local and global companies’ presence. Pfizer Inc., Lupin Laboratories Ltd, AstraZeneca, Novartis, Cipla, Alkem Laboratories, Cadila pharmaceuticals, Johnson & Johnson, Sanofi, Macleod Pharmaceuticals and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in Oct 2022, Lupin announced its agreement with global agencies, including Unitaid, Clinton health access initiative, The Arum institute and some other agencies, to provide support for the prevention treatment of tuberculosis that will be implemented in 138 countries. From this tie, two new formulations will be introduced at a minimal price by Lupin, rifapentine 300 mg standalone tablets and a combination of rifapentine and isoniazid. 

Pfizer Inc.:


Pfizer Inc. is a multinational pharmaceutical corporation that also works in the biotechnology domain. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, and immunology.

Product Portfolio:

Trecator: Trecator is a drug used for active tuberculosis treatment in patients with M. tuberculosis that are resistant to rifampin or isoniazid. Ethionamide is its chemical name. Its alone usage in tuberculosis treatment provides rapid resistance development. 

The global tuberculosis drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages. 

Trending Topics

Drug Delivery Devices Market

Drug Screening Market

LIchen Sclerosus Treatment Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy